{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:02:53Z","timestamp":1771927373351,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To evaluate the impact of lotilaner ophthalmic solution, 0.25%, compared to vehicle, on disease severity in patients with\n                      <jats:italic>Demodex<\/jats:italic>\n                      blepharitis and meibomian gland disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This post-hoc analysis pooled data from two prospective, randomized, double-masked studies evaluating lotilaner ophthalmic solution, 0.25% (Ersa,\n                      <jats:italic>N<\/jats:italic>\n                      \u202f=\u202f39) and vehicle (Rhea,\n                      <jats:italic>N<\/jats:italic>\n                      \u202f=\u202f40) in\n                      <jats:italic>Demodex<\/jats:italic>\n                      blepharitis patients with meibomian gland disease. The study utilized a modified International Workshop on Meibomian Gland Dysfunction (IWMGD) severity scale, integrating meibomian gland secretion score (MGSS) and patient-reported visual analog scale for fluctuating vision (VASFLVIS), and categorized meibomian gland disease severity as Grade 1 (subclinical), Grade 2 (mild), Grade 3 (moderate), or Grade 4 (severe). The main outcome was changes in severity grades from baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, meibomian gland disease severity was comparable between groups. At Day 43, 47% of lotilaner-treated patients achieved Grade \u22642 (mild or better), significantly greater than 21% of vehicle-treated patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.02). At Day 85, the difference increased, with 63% in the lotilaner group achieving Grade \u22642 versus 24% in the vehicle group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). For grade improvement, at Day 43, 63% of lotilaner-treated patients versus 38% of vehicle-treated patients achieved \u22651 grade improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.035); and at Day 85, 74% versus 39%, respectively, achieved \u22651 grade improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004). No serious treatment-related adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Lotilaner ophthalmic solution, 0.25% significantly improved meibomian gland disease severity in patients with\n                      <jats:italic>Demodex<\/jats:italic>\n                      blepharitis and concomitant meibomian gland disease at 6 and 12\u202fweeks compared to vehicle.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1719825","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:00:11Z","timestamp":1769169611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of lotilaner ophthalmic solution 0.25% on disease severity in patients with Demodex blepharitis and meibomian gland disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Bridgitte","family":"Shen Lee","sequence":"first","affiliation":[{"name":"Vision Optique","place":["Houston, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Yeu","sequence":"additional","affiliation":[{"name":"Tarsus Pharmaceuticals, Inc.","place":["Irvine, CA, United States"]},{"name":"Virginia Eye Consultants","place":["Norfolk, VA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Dhamdhere","sequence":"additional","affiliation":[{"name":"Tarsus Pharmaceuticals, Inc.","place":["Irvine, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Donnenfeld","sequence":"additional","affiliation":[{"name":"Ophthalmic Consultants of Long Island","place":["Long Island, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","article-title":"Dry eye disease associated with Meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape","volume":"12","author":"Sheppard","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/OPTH.S428468","article-title":"Risk factors for Meibomian gland disease assessed by Meibography","volume":"17","author":"Kim","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/opx.0000000000002053","article-title":"Localized heat treatment for meibomian gland dysfunction: a single-center retrospective analysis of efficacy over time","volume":"100","author":"Chester","year":"2023","journal-title":"Optom Vis Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1167\/iovs.10-6997","article-title":"The international workshop on meibomian gland dysfunction: introduction","volume":"52","author":"Nichols","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1717118","DOI":"10.3389\/fmed.2025.1717118","article-title":"Alterations in the composition of meibomian gland secretions in patients with meibomian gland dysfunction based on Raman spectroscopy","volume":"12","author":"Ou","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41598-021-04167-x","article-title":"A multi-center study evaluating the correlation between meibomian gland dysfunction and depressive symptoms","volume":"12","author":"Wei","year":"2022","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e15595","DOI":"10.1097\/MD.0000000000015595","article-title":"The correlation between the microstructure of meibomian glands and ocular Demodex infestation: a retrospective case-control study in a Chinese population","volume":"98","author":"Cheng","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/ICL.0000000000001003","article-title":"Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies","volume":"49","author":"Rhee","year":"2023","journal-title":"Eye Contact Lens"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ACI.0b013e32833df9f4","article-title":"Pathogenic role of Demodex mites in blepharitis","volume":"10","author":"Liu","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref13","first-page":"15","article-title":"Demodex sp. infestation in anterior blepharitis, meibomian-gland dysfunction, and mixed blepharitis","volume":"36","author":"Lim-Bon Siong","year":"2011","journal-title":"Philipp J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/OPTH.S354692","article-title":"The prevalence of Demodex blepharitis in US eye care clinic patients as determined by Collarettes: a pathognomonic sign","volume":"16","author":"Trattler","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/ICO.0000000000001361","article-title":"Ocular Demodicosis as a potential cause of ocular surface inflammation","volume":"36","author":"Luo","year":"2017","journal-title":"Cornea"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/ICO.0000000000002837","article-title":"TearCare for the treatment of Meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial","volume":"41","author":"Gupta","year":"2022","journal-title":"Cornea"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/ICO.0b013e318239aaea","article-title":"A new system, the LipiFlow, for the treatment of meibomian gland dysfunction","volume":"31","author":"Lane","year":"2012","journal-title":"Cornea"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/OPTH.S234008","article-title":"Comparison of the iLUX and the LipiFlow for the treatment of Meibomian gland dysfunction and symptoms: a randomized clinical trial","volume":"14","author":"Tauber","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ophtha.2023.05.030","article-title":"Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, Multicenter, phase 3 trial (Saturn-2)","volume":"130","author":"Gaddie","year":"2023","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"101492","DOI":"10.1016\/j.clae.2021.101492","article-title":"Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: a randomized, controlled, double-masked clinical trial","volume":"45","author":"Gonzalez-Salinas","year":"2022","journal-title":"Cont Lens Anterior Eye"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1080\/09273948.2022.2093755","article-title":"Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical Lotilaner ophthalmic solution, 0.25% Eyedrops to vehicle","volume":"31","author":"Yeu","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/ICO.0000000000003097","article-title":"Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)","volume":"42","author":"Yeu","year":"2023","journal-title":"Cornea"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10792-016-0249-9","article-title":"Demodex species in human ocular disease: new clinicopathological aspects","volume":"37","author":"Nicholls","year":"2017","journal-title":"Int Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/j.jcrs.0000000000001619","article-title":"Meibomian gland structure and function in patients with Demodex blepharitis","volume":"51","author":"Yeu","year":"2025","journal-title":"J Cataract Refract Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","article-title":"Management of meibomian gland dysfunction: a review","volume":"65","author":"Sabeti","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.ophtha.2023.07.009","article-title":"Thermal pulsation in the management of meibomian gland dysfunction and dry eye: a report by the American Academy of ophthalmology","volume":"130","author":"Tao","year":"2023","journal-title":"Ophthalmology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/jop.2023.0080","article-title":"Evaluation of the impact of meibomian gland dysfunction using a novel patient-reported outcome instrument","volume":"40","author":"Ajouz","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jtos.2021.10.003","article-title":"Alteration in meibum lipid composition and subjective symptoms due to aging and meibomian gland dysfunction","volume":"26","author":"Suzuki","year":"2022","journal-title":"Ocul Surf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/ico.0000000000000998","article-title":"Mechanisms of visual disturbance in dry eye","volume":"35","author":"Koh","year":"2016","journal-title":"Cornea"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1167\/iovs.10-7051","article-title":"Estimating a just-noticeable difference for ocular comfort in contact lens wearers","volume":"52","author":"Papas","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1719825\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:10:38Z","timestamp":1771924238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1719825\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1719825"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1719825","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1719825"}}